Immediate Impact
57 standout
Citing Papers
Bispecific and multispecific antibodies in oncology: opportunities and challenges
2024 Standout
Bispecific antibody drug conjugates: Making 1+1>2
2024 Standout
Works of Frank Seebach being referenced
Preliminary results from a phase 1/2 study of co-stimulatory bispecific PSMAxCD28 antibody REGN5678 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
2023
A phase 1/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with mesenchymal epithelial transition factor (MET)-overexpressing NSCLC.
2022
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Frank Seebach | 154 | 85 | 55 | 105 | 35 | 388 | |
| M. Coviello | 110 | 56 | 19 | 98 | 24 | 433 | |
| K Inada | 74 | 94 | 22 | 150 | 25 | 430 | |
| A. Cooper | 133 | 67 | 12 | 58 | 25 | 368 | |
| Shigeaki Takeda | 107 | 70 | 19 | 41 | 35 | 439 | |
| Feng Wang | 47 | 42 | 30 | 153 | 33 | 402 | |
| Fabio Ferrando | 146 | 29 | 16 | 92 | 22 | 373 | |
| Hiroyuki Watanabe | 213 | 92 | 18 | 65 | 37 | 399 | |
| Taisuke Baba | 62 | 82 | 69 | 128 | 25 | 339 | |
| Angela Damato | 196 | 61 | 16 | 129 | 38 | 396 | |
| Mitsuru Yoshimoto | 177 | 29 | 22 | 135 | 37 | 425 |
All Works
Loading papers...